For Healthcare Professionals

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

clipboard-pencil

About the study

The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Males and Females at least 18 years of age
  2. Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery
  3. ECOG Performance status of 0 or 1
  4. Available tumor sample for testing
  5. Acceptable blood work

EXCLUSION CRITERIA

  1. Primitive peritoneal, pericardial and tunica vaginalis testis mesotheliomas
  2. Prior chemotherapy for pleural mesothelioma
  3. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 oranti-CTLA-4 antibody
  4. History of other malignancy unless the subject has been disease-free for at least 3 years
  5. Active, untreated central nervous system (CNS) metastasis Other protocol defined inclusion/exclusion criteria could apply
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Email iconEmail Study Center

Study’s details


Contition

Mesothelioma

Age

18+

Phase

Phase 3

Participants needed

605

Est. Completion Date

Apr 2023

Treatment type

Interventional


Sponsor

Bristol-Myers Squibb

ClinicalTrials.gov identifier

NCT02899299

Study number

CA209743

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.